** Shares of India's Sun Pharma SUN.NS climb 3% to 1,656.25 rupees
** SUN top pct gainer on pharma index .NIPHARM and second-biggest gainer on Nifty 50 .NSEI
** India's top drugmaker by revenue to acquire U.S.-based Checkpoint Therapeutics CKPT.O for $355 million
$1 BILLION OPPORTUNITY
** JP Morgan ("overweight", PT: 2,210 rupees) says Checkpoint acquisition "checks the boxes" as it gives SUN access to a US FDA approved skin cancer drug Unloxcyt, which has potential to become a $1 billion opportunity in US
** Adds, acquisition will bolster SUN's specialty offerings in skin cancer space, which has been one of its key focus areas
** BofA Securities ("neutral", PT: 1,940 rupees) says Unloxcyt has an advantage over rivals' drugs due to lower price, but says it awaits clarity on SUN's commercial strategy
** Motilal Oswal ("buy", PT: 1,895 rupees) says SUN is "on a spree to expand specialty portfolio" and Checkpoint's five cancer treatment assets to complement SUN's existing portfolio
(Reporting by Kashish Tandon in Bengaluru)
((Kashish.tandon@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。